Answers are grounded in this paper and cite their sources.
Objective To investigate N-myc downstream-regulated gene 2 (NDRG2) expression in ovarian cancer cells and its potential usefulness as a diagnostic marker and/or target for therapeutic intervention. Methods Human NDRG2L/S gene was obtained by revers-transcription polymerase chain reaction (RT-PCR). Sequence analysis confirmed the identity of NDRG2L/S gene, which was then inserted into a eukaryotic vector pLNCX2, which was in turn transfected into NDRG2 gene-negative HO-8910 cells. Flow cytometry (FCM) and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay were conducted to determine the proliferation rate of HO-8910 cells. Cisplatin resistance of HO-8910 cells transfected with pLNCX2-NDRG2L/S was evaluated by FCM. Tumors were generated in female nude mice by subcutaneous injection of HO-8910 cells. Results NDRG2 gene was isolated and its expression vector was successfully constructed. NDRG2 expression positively correlated with the proliferation of HO-8910 cells. NDRG2L/S promoted tumorigenicity in HO-8910 cells. Conclusion The present study identified a novel function of NDRG2L/S gene and demonstrated its involvement in the promotion of ovarian cancer cell proliferation and enhancement of cisplatin resistance in HO-8910 cells. Future studies are warranted to determine the relationship between NDRG2 upregulation and ovarian cancer progression.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: